SERUM INSTITUTE OF INDIA
Significant contributions to the BioEconomy and the global acceptance of biosimilar products are driving an expected growth to nearly US$ 63 billion by 2025, indicating a promising trajectory.
Serum Institute of India Pvt. Ltd. manufactures several vaccines, which include Polio, Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps and Rubella vaccines. 65% of children in the world are estimated to receive at least one vaccine manufactured by Serum Institute. Vaccines manufactured by the Serum Institute are accredited by the World Health Organization.
- Founded in 1966 with the aim to manufacture immune biologicals, which were short in India and imported at higher prices.
- Manufactures life-saving biologicals at affordable prices.
- Serum vaccines are used in ~170 countries in their national immunisation programmes.
Serum Institute of India – Protection from birth onwards
| Year | Milestone |
|---|---|
| 2024 |
In May 2024, The Serum Institute of India (SII), has invested strategically in IntegriMedical, securing a 20% stake in the company to propel Needle-Free Injection System technology forward. In February 2024, Serum Institute has announced New Phase 3 Trial Data Confirm the Uniquely High Efficacy and Good Safety Profile of the R21/Matrix-M™ Malaria Vaccine in African Children In January 2024, Serum Institute of India joins CEPI global network to boost production of affordable outbreak vaccines. |
| 2023 |
In November 2023, Serum Institute has announced to start Phase I & II trials of dengue vaccine in India. In October 2023, WHO approves world’s 2nd malaria vaccine by Oxford-Serum Institute. In August 2023, Serum Institute of India CEO, Mr. Adar Poonawalla received the ‘Udyog Mitra’ award from the Government of Maharashtra. In July 2023, MenFive®, the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). In July 2023, UK Minister Mr. George Freeman visits Serum Institute of India. In May 2023, the International Society for Pharmaceutical Engineering (ISPE) awards Serum Institute of India, the 2023 Facility of the Year Category Award for Supply Chain and Social Impact. In April 2023, Serum Institute restarts manufacturing of Covishield vaccine as Covid cases surge. In April 2023, Serum Institute launches country’s first HPV vaccine, ‘CERVAVAC’. It has been jointly created by the Serum Institute of India and the Department of Biotechnology. In April 2023, The University of Oxford-developed and Serum Institute of India (SII) manufactured and scaled up R21/Matrix-M malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority (FDA). In April 2023, Serum Institute of Life Sciences announced to double up its investment in Biocon's unit to US$ 300 million. With this, Biocon's unit will also get access to SILS' 100 million vaccine doses annually. In February 2023, Serum Institute of India announces centre of excellence in Hyderabad to tackle future pandemics. In January 2023, Serum Institute of India launched the first made-in-India qHPV vaccine 'CERVAVAC'. In January 2023, Serum Institute of India CEO Adar Poonawalla received ‘Dr. Patangrao Kadam Memorial Award’. |
| 2022 |
In September 2022, India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine 'CERVAVAC' was announced for the prevention of cervical cancer. Serum Institute of India (SII), the Department of Biotechnology (DBT), the Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation collaborated to develop this vaccine. In September 2022, Serum Institute of India received 'Happiest Workplace Award – 2022'. Serum Institute of India (SII) plans to launch the country’s first indigenous HPV vaccine to combat cervical cancer in the near future. |
| 2021 |
In December 2021, Serum Institute of India pledged US$ 66.2 million to the University of Oxford to setup a research campus. In November 2021, Serum Institute of India crossed the 1 billion doses of Covishield vaccine production milestone. Serum Institute Life Sciences Private Limited (SILS) and Biocon Biologics Limited (BBL) announced a strategic alliance to develop antibodies for infectious diseases such as dengue, HIV, and others. In June 2021, SII announced plans to launch Novavax's COVID-19 vaccine 'Covovax' in India by September 2021 Government of India signed a deal to procure 20 million doses of its COVID-19 vaccination. |
| 2020 |
Launched India’s first fully indigenously developed pneumococcal vaccine, 'Pneumosil' |
| 2016 |
Launched world’s first rabies human monoclonal antibody, recombinant |
| 2014 |
Launched oral polio vaccine |
| 2012 |
Acquired Bilthoven Biologicals, Netherlands |
| 2011 |
Launched injectable inactivated polio vaccine |
| 2010 |
Launched H1N1 influenza vaccine |
| 2009 |
Launched liquid pentavalent vaccine (DPT-HepB-Hib) (PENAVAC SD/PFS) |
| 2007 |
Launched Hib vaccine and BCG vaccine for bladder cancer |
| 2002 |
Launched BCG vaccine |
| 2001 |
Launched Hepatitis B vaccine |
| 1993 |
Launched MMR vaccine |
| 1989 |
Launched measles vaccine |
| 1974 |
Commenced production of DTP vaccine |
Partners
